These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27863422)

  • 21. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
    Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
    Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.
    González I; Vicent S; de Alava E; Lecanda F
    J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
    Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
    J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
    Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
    Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.
    Zwerner JP; May WA
    Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel approaches for the management of patients with Ewing sarcoma.
    Avigad S; Yaniv I
    Future Oncol; 2006 Oct; 2(5):659-65. PubMed ID: 17026457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
    Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
    Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.
    Huang L; Nakai Y; Kuwahara I; Matsumoto K
    Cancer Res; 2012 Mar; 72(5):1260-9. PubMed ID: 22241085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
    Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
    Sun H; Lin DC; Cao Q; Pang B; Gae DD; Lee VKM; Lim HJ; Doan N; Said JW; Gery S; Chow M; Mayakonda A; Forscher C; Tyner JW; Koeffler HP
    Clin Cancer Res; 2017 Aug; 23(15):4376-4387. PubMed ID: 28336564
    [No Abstract]   [Full Text] [Related]  

  • 37. Cruel fusion: What a young man's death means for childhood cancer.
    Ledford H
    Nature; 2017 Mar; 543(7647):608-611. PubMed ID: 28358102
    [No Abstract]   [Full Text] [Related]  

  • 38. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Garnett MJ; Edelman EJ; Heidorn SJ; Greenman CD; Dastur A; Lau KW; Greninger P; Thompson IR; Luo X; Soares J; Liu Q; Iorio F; Surdez D; Chen L; Milano RJ; Bignell GR; Tam AT; Davies H; Stevenson JA; Barthorpe S; Lutz SR; Kogera F; Lawrence K; McLaren-Douglas A; Mitropoulos X; Mironenko T; Thi H; Richardson L; Zhou W; Jewitt F; Zhang T; O'Brien P; Boisvert JL; Price S; Hur W; Yang W; Deng X; Butler A; Choi HG; Chang JW; Baselga J; Stamenkovic I; Engelman JA; Sharma SV; Delattre O; Saez-Rodriguez J; Gray NS; Settleman J; Futreal PA; Haber DA; Stratton MR; Ramaswamy S; McDermott U; Benes CH
    Nature; 2012 Mar; 483(7391):570-5. PubMed ID: 22460902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy.
    Shenoy N
    Cancer; 2020 Dec; 126(24):5198-5201. PubMed ID: 33048366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.